Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vizcof Linctus is an oral combination syrup developed by Minova Life Sciences for the treatment of productive cough, chest congestion, and respiratory symptoms associated with conditions such as bronchitis, bronchial asthma, and allergies. It contains five active ingredients: bromhexine (a mucolytic that thins and loosens phlegm), guaifenesin (an expectorant that increases airway fluid volume to facilitate mucus clearance), dextromethorphan (a centrally acting antitussive that suppresses the cough reflex), chlorpheniramine (an antihistamine that relieves allergy-related symptoms), and menthol (a cooling agent that soothes minor throat irritation). Together, these components provide a comprehensive approach to easing breathing and relieving cough discomfort.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bromhexine + chlorpheniramine + dextromethorphan + guaifenesin + menthol.